Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503429 | 0.84 | CA12 (0.71) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31406172 | 0.84 | CA12 (0.71) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL195793 | 0.84 | ALDH1A1 (0.56) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31003218 | 0.84 | ALDH1A1 (0.56) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16953406 | 0.83 | TSHR (0.45) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29399077 | 0.83 | TSHR (0.73) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27753902 | 0.83 | TSHR (0.73) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL76834 | 0.83 | TSHR (0.73) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL2377733 | 0.82 | CA12 (0.69) | LMNATSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1757167 | 0.82 | MAPT (0.64) | LMNATSHRCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064823-A1 | THIADIAZINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2025-02-27 | — | — | US | disclosed |
| US-12194050-B2 | Thiadiazine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-01-14 | — | — | US | disclosed |
| WO-2023192348-A1 | CONFORMATIONALLY GATED OPTOELECTRONIC MOLECULAR RECTIFIERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3820865-A1 | THIADIAZINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2021-05-19 | — | — | EP | disclosed |
| US-10912767-B2 | Anthracycline prodrugs and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2020012423-A1 | THIADIAZINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2020-01-16 | — | — | WO | disclosed |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009125870-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | WO | disclosed |
| US-20080312319-A1 | Modulation of Bacterial Quorum Sensing with Synthetic Ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-18 | — | — | US | disclosed |
| WO-2008116029-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20070092467-A1 | Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers | L'OREAL (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070092467-A1 | Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers | L'OREAL (FR) | 2007-04-26 | — | — | US | disclosed |
| WO-2004024074-A2 | FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-0191496-B1 | TRIAZINE DERIVATIVES, A PROCESS FOR PREPARING THE DERIVATIVES, AND HERBICIDES CONTAINING THE DERIVATIVES AS THE EFFECTIVE COMPONENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
| US-4680054-A | Triazine derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1987-07-14 | — | — | US | disclosed |
| EP-0191496-A2 | Triazine Derivatives, a process for preparing the derivatives, and herbicides containing the derivatives as the effective component | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194050-B2 | Thiadiazine derivatives | CHRNA5, CHRNA7, CHRNA1 | LMNA 2599/4885TSHR 202/4885CYP1A2 169/4885 |
| US-20070092467-A1 | Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers | HPGD, KRT18, PTGS1 | LMNA 2229/4885TSHR 3363/4885CYP1A2 297/4885 |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | LMNA 1777/4885TSHR 4355/4885CYP1A2 4821/4885 |
| US-20080312319-A1 | Modulation of Bacterial Quorum Sensing with Synthetic Ligands | AHCYL1, EBPL, AIP | LMNA 3895/4885TSHR 2075/4885CYP1A2 3568/4885 |
| US-10912767-B2 | Anthracycline prodrugs and methods of making and using the same | TET3, DPYD, CYP2C9 | LMNA 422/4885TSHR 4458/4885CYP1A2 25/4885 |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | LMNA 3095/4885TSHR 2464/4885CYP1A2 4883/4885 |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | LMNA 3399/4885TSHR 681/4885CYP1A2 2168/4885 |
| US-20250064823-A1 | THIADIAZINE DERIVATIVES | CHRNA5, CHRNA7, CHRM5 | LMNA 2462/4885TSHR 191/4885CYP1A2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.